Showing 7281-7290 of 7715 results for "".
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma L
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutation
- NeoStrata Launches Exuviance Triple Microdermabrasionhttps://practicaldermatology.com/news/20140530-neostrata_launches_exuviance_triple_microdermabrasion/2459226/NeoStrata Company's new Exuviance Triple Microdermabrasion, described as a three-part approach to skin renewal in one single treatment, will be available nationwide in August. Exuviance Triple Microdermabrasion is formulated with professional grade crystals and Papaya Enzymes along with 1
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- iMatrix Launches New Web Marketing Services for Dermatologistshttps://practicaldermatology.com/news/20140520-imatrix_launches_new_web_marketing_services_for_dermatologists/2459235/iMatrix, division of Internet Brands, Inc. revealed new online marketing services for dermatologists, including marketing solutions, including professionally designed websites, social media management, video marketing, pay-per-click advertising, and a comprehensive SEO/SEM service called Dominato
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- The XV World Congress on Cancers of the Skin to be Held in Edinburghhttps://practicaldermatology.com/news/20140501-the_xv_world_congress_on_cancers_of_the_skin_to_be_held_in_edinburgh/2459248/The XV World Congress on Cancers of the Skin, co-sponsored by The Skin Cancer Foundation and the British Association of Dermatologists, will be held at the Edinburgh International Conference Centre in Edinburgh, Scotland, September 3-6, 2014. The World Congress provides an opportunity for physic